SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

Enrollment Complete in First Two Cohorts of Phase 2 Early-Onset Fetal Growth Restriction Trial; KOL

DMAC

Related stories